


Lanicemine

Cat. No.:	HY-108235	
CAS No.:	153322-05-5	
Molecular Formula:	C ₁₃ H ₁₄ N ₂	
Molecular Weight:	198.26	
Target:	iGluR	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling	
Storage:	Pure form	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



BIOLOGICAL ACTIVITY

Description	Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (K _i of 0.56-2.1 μM for NMDA receptor; IC ₅₀ s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects ^[1] .	
IC₅₀ & Target	NMDA receptor ^[1]	
In Vivo	Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects ^[1] . Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Sprague-Dawley rats ^[1]
	Dosage:	3, 10 or 30 mg/kg
	Administration:	Intraperitoneal
	Result:	Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity.

REFERENCES

[1]. Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. *Mol Psychiatry*. 2014 Sep;19(9):978-85.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA